Delivery Order SPE2DB22D2007-SPE2DB25FJ3MJ
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,691.58 to AmerisourceBergen Drug Corp for the supply of Ibsrela 50 mg tablets (60-count units) under a firm fixed-price contract. The award was made on July 21, 2025, with an ultimate completion date of July 22, 2025, and represents a non-set-aside, competitively awarded procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Ibsrela 50 mg tablets (60 count) with a ceiling value of $10,513.99. This firm fixed-price delivery order, which is not set-aside for small business or other designated groups, is scheduled for completion by August 1, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a $10,409.44 firm fixed-price delivery order to AmerisourceBergen Drug Corp for IBSRELA 50 mg tablets (60-count units) on July 30, 2025, with an ultimate completion date of July 31, 2025. This non-competitive delivery order was performed at the contractor's corporate office location in Conshohocken, Pennsylvania, and represents a routine pharmaceutical procurement supporting federal medical supply needs. The award is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,204.14 to AmerisourceBergen Drug Corp for IBSRELA 50 mg tablets (60 count) on July 23, 2025, with an ultimate completion date of July 24, 2025. This non-set-aside contract utilizes firm fixed price terms and represents a child delivery order under AmerisourceBergen's larger federal pharmaceutical supply agreements. The work will be performed at the vendor's corporate office in Conshohocken, Pennsylvania. This delivery order is...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $3,266.36 by the Defense Logistics Agency (DLA) on July 18, 2025, with an ultimate completion date of July 21, 2025. The contract, which is not set-aside and competitively awarded, calls for the delivery of Ibsrela 50 mg tablets in quantities of 60 units. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $72,986.26 firm fixed-price contract is for the delivery of IBSRELA 50 MG TABLET UU 60S, a pharmaceutical product. The contract has a completion date of June 18, 2025 and is not set aside. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of IBSRELA 50 MG TABLET in 60-count units. The contract has a firm fixed price, with a ceiling value of $2,653.11, and an ultimate completion date of May 19, 2025. The contract is not set aside and is an open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- The Defense Logistics Agency awarded a $5,206.86 firm fixed price delivery order to Amerisourcebergen Drug Corporation for the supply of 4561986967 IBSRELA 50 MG tablets. As the prime contractor, Amerisourcebergen Drug Corporation will deliver 60 count bottles of the specified medication to a facility in Conshohocken, Pennsylvania by August 30, 2023 under the terms of the order. The Defense Logistics Agency is the Department of Defense's combat logistics support agency, indicating this...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $24,047.92, is a Firm Fixed Price Delivery Order for the medical product IBSRELA 50 MG TABLET UU 60S. The contract has a period of performance ending on November 27, 2024. No set-aside designation was used for this award. AmerisourceBergen holds a significant Indefinite...
- This is a $15,052.01 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of IBSRELA 50 MG TABLET UU 60S, a pharmaceutical product, with a performance period ending on July 1, 2025. This delivery order is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, which provides a comprehensive...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ3MJDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Ibsrela 50 mg tablets (60 count) under a firm fixed-price contract valued at $4,847.75. This non-set-aside award is a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion vehicle that runs through December 2026 and supports pharmaceutical procurement for military and veteran healthcare systems worldwide. The delivery order is scheduled for completion by August 1, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, has demonstrated substantial capacity to fulfill federal medical supply requirements through competitive procurement processes. As a critical vendor in the Defense Health Agency supply chain, the company supplies a comprehensive portfolio of pharmaceuticals including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. This delivery order for Ibsrela, a gastrointestinal medication, represents a routine transaction within the company's ongoing support of federal healthcare procurement needs through the DLA's global pharmaceutical support framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.8k | 7/31/25 |